Lynch & Associates Bristol Myers Squibb CO Transaction History

Lynch & Associates

$467 Million
Q3 2024

A detailed history of Lynch & Associates transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Lynch & Associates holds 7,224 shares of BMY stock, worth $400,570. This represents 0.08% of its overall portfolio holdings.

Number of Shares

7,224

Previous 7,709 6.29%

Holding current value

$400,570

Previous $320,000 16.56%

% of portfolio

0.08%

Previous 0.07%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	SELL	$39.66 - $51.75 $19,235 - $25,098	-485 Reduced 6.29%	7,224 $373,000
Q2 2024 Aug 06, 2024	SELL	$40.25 - $52.99 $13,846 - $18,228	-344 Reduced 4.27%	7,709 $320,000
Q1 2024 Apr 09, 2024	SELL	$47.98 - $54.4 $59,974 - $68,000	-1,250 Reduced 13.44%	8,053 $436,000
Q4 2023 Jan 08, 2024	SELL	$48.48 - $57.85 $19,828 - $23,660	-409 Reduced 4.21%	9,303 $477,000
Q3 2023 Oct 24, 2023	BUY	$57.89 - $64.73 $61,942 - $69,261	1,070 Added 12.38%	9,712 $563,000
Q2 2023 Oct 24, 2023	SELL	$63.71 - $70.74 $3,058 - $3,395	-48 Reduced 0.55%	8,642 $552,000
Q2 2023 Jul 13, 2023	SELL	$63.71 - $70.74 $3,058 - $3,395	-48 Reduced 0.55%	8,642 $553,000
Q1 2023 Oct 24, 2023	BUY	$65.71 - $74.53 $3,154 - $3,577	48 Added 0.56%	8,690 $602,000
Q1 2023 Apr 04, 2023	SELL	$65.71 - $74.53 $11,564 - $13,117	-176 Reduced 1.99%	8,690 $602,000
Q4 2022 Oct 24, 2023	SELL	$68.48 - $81.09 $57,934 - $68,602	-846 Reduced 8.71%	8,866 $637,000
Q4 2022 Jan 05, 2023	SELL	$68.48 - $81.09 $8,902 - $10,541	-130 Reduced 1.45%	8,866 $638,000
Q1 2022 Apr 08, 2022	SELL	$61.48 - $73.72 $14,755 - $17,692	-240 Reduced 2.6%	8,996 $657,000
Q4 2021 Jan 11, 2022	BUY	$53.63 - $62.52 $35,932 - $41,888	670 Added 7.82%	9,236 $576,000
Q2 2021 Jul 21, 2021	SELL	$61.91 - $67.42 $19,192 - $20,900	-310 Reduced 3.49%	8,566 $572,000
Q3 2020 Oct 21, 2020	SELL	$57.43 - $63.64 $86,145 - $95,460	-1,500 Reduced 14.46%	8,876 $535,000
Q2 2020 Jul 20, 2020	SELL	$54.82 - $64.09 $88,808 - $103,825	-1,620 Reduced 13.5%	10,376 $610,000
Q1 2020 Apr 28, 2020	BUY	$46.4 - $67.43 $232 - $337	5 Added 0.04%	11,996 $669,000
Q3 2019 Oct 03, 2019	SELL	$42.77 - $50.71 $10,478 - $12,423	-245 Reduced 2.0%	11,991 $608,000
Q2 2019 Jul 19, 2019	SELL	$44.62 - $49.34 $56,533 - $62,513	-1,267 Reduced 9.38%	12,236 $555,000
Q4 2018 Jan 10, 2019	SELL	$48.76 - $63.23 $1,462 - $1,896	-30 Reduced 0.22%	13,503 $702,000
Q2 2018 Jul 09, 2018	SELL	$50.53 - $62.98 $28,549 - $35,583	-565 Reduced 4.01%	13,533 $749,000
Q1 2018 Apr 06, 2018	SELL	$59.92 - $68.98 $98,868 - $113,817	-1,650 Reduced 10.48%	14,098 $892,000
Q4 2017 Jan 04, 2018	SELL	$59.94 - $65.35 $7,192 - $7,841	-120 Reduced 0.76%	15,748 $965,000
Q3 2017 Oct 18, 2017	BUY	$55.23 - $63.74 $876,389 - $1.01 Million	15,868	15,868 $1.01 Million

Others Institutions Holding BMY

# of Institutions

2,453

Shares Held

1.5B

Call Options Held

29.6M

Put Options Held

32.1M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $118B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynch & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Lynch & Associates with notifications on news.

Account

Lynch & Associates Bristol Myers Squibb CO Transaction History